| Literature DB >> 28817687 |
Franziska Heinrich1,2, Annika Lehmbecker1,2, Barbara B Raddatz1,2, Kristel Kegler1,2, Andrea Tipold2,3, Veronika M Stein2,4, Arno Kalkuhl5, Ulrich Deschl5, Wolfgang Baumgärtner1,2, Reiner Ulrich1,6, Ingo Spitzbarth1,2.
Abstract
Macrophages are a heterogeneous cell population playing a pivotal role in tissue homeostasis and inflammation, and their phenotype strongly depends on the micromilieu. Despite its increasing importance as a translational animal model for human diseases, there is a considerable gap of knowledge with respect to macrophage polarization in dogs. The present study comprehensively investigated the morphologic, phenotypic, and transcriptomic characteristics of unstimulated (M0), M1- (GM-CSF, LPS, IFNγ-stimulated) and M2- (M-CSF, IL-4-stimulated)-polarized canine blood-derived macrophages in vitro. Scanning electron microscopy revealed distinct morphologies of polarized macrophages with formation of multinucleated cells in M2-macrophages, while immunofluorescence employing literature-based prototype-antibodies against CD16, CD32, iNOS, MHC class II (M1-markers), CD163, CD206, and arginase-1 (M2-markers) demonstrated that only CD206 was able to discriminate M2-macrophages from both other phenotypes, highlighting this molecule as a promising marker for canine M2-macrophages. Global microarray analysis revealed profound changes in the transcriptome of polarized canine macrophages. Functional analysis pointed out that M1-polarization was associated with biological processes such as "respiratory burst", whereas M2-polarization was associated with processes such as "mitosis". Literature-based marker gene selection revealed only minor overlaps in the gene sets of the dog compared to prototype markers of murine and human macrophages. Biomarker selection using supervised clustering suggested latexin (LXN) and membrane-spanning 4-domains, subfamily A, member 2 (MS4A2) to be the most powerful predicting biomarkers for canine M1- and M2-macrophages, respectively. Immunofluorescence for both markers demonstrated expression of both proteins by macrophages in vitro but failed to reveal differences between canine M1 and M2-macrophages. The present study provides a solid basis for future studies upon the role of macrophage polarization in spontaneous diseases of the dog, a species that has emerging importance for translational research.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28817687 PMCID: PMC5560737 DOI: 10.1371/journal.pone.0183572
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
List of antibodies used for immunofluorescence.
| Polarity | Antigen | Clone | Clonality | Source | Dilution |
|---|---|---|---|---|---|
| M1 | CD16 | LNK16 | Monoclonal mouse | Abcam | 1:20 |
| CD32 | AT10 | Monoclonal mouse | Abcam | 1:10 | |
| MHC class II | Dog 26 | Monoclonal rat | Helmholtz Zentrum | 1:10 | |
| iNOS | n.a. | Polyclonal rabbit | Merck Milipore | 1:50 | |
| LXN | n.a. | Polyclonal goat | Biologo | 1:10 | |
| M2 | MS4A2 | n.a. | Polyclonal rabbit | Biologo | 1:10 |
| CD163 | AM-3K | Monoclonal mouse | TransGenic Inc. | 1:20 | |
| CD206 | 3.29B1.10 | Monoclonal mouse | BeckmanCoulter Inc. | 1:20 | |
| Arginase-1 | n.a. | Polyclonal rabbit | Sigma Aldrich | 1:125 |
CD, cluster of differentiation; MHC, major histocompatibility complex; iNOS, inducible nitric oxide synthase, LXN, latexin; n.a. = not applicable
‡Cambridge, UK
†kindly provided by Dr. E Kremmer, Institute of Molecular Immunology, Helmholtz Zentrum, München, German Research Center for Environmental Health (GmbH), Munich, Germany
᛭Darmstadt, Germany
‖Kobe, Japan
¶Krefeld, Germany
§ Taufkirchen, Germany
* Kronshagen, Germany
Fig 1Polarization-dependent morphological differences in canine M0-, M1-, and M2-macrophage cultures.
A) In scanning electron microscopy, unstimulated macrophages (M0; day 7) obtain a small and roundish morphology, lacking cytoplasmic extensions. B) M1-treated macrophages (day 7) are characterized by an enlarged amoeboid cell shape with roundish cell bodies and numerous delicate cytoplasmic extensions on the cellular surface. C; D) M2-treated macrophage cultures (day 7) demonstrate a marked heterogeneity with two dominating cell types. Large “spindeloid” macrophages with an elongated cell body and cytoplasmic extensions on the apical ends of the cell bodies (C). Second, in M2-cultures, numerous multinucleated giant cells (MNGs) with abundant cytoplasmic projections on the cellular surface are present (D). E-H) Dot plot diagrams depicting the morphological changes of macrophage cultures (n = 3) following stimulation (M0, M1, M2) over the time course as calculated with a mixed ANOVA with post-hoc alpha adjustment (Tukey-Kramer) and significance level at p≤0.05 (asterisks). E) Small/roundish macrophages dominate in untreated M0 cell cultures and their relative percentage is significantly higher in M0 when compared to M2 at days 5 and 7. F) Amoeboid macrophages display a statistical trend of predominance in M1 compared to M0 at day 5 and 7. G) The relative percentage of spindeloid macrophages is significantly increased in M2 at day 5 compared to M1. H) MNGs are almost exclusively observed in M2-macrophages at the end of the culturing period and their percentage is significantly higher at day 7 in M2 compared to both M0 and M1.
Fig 2Immunofluorescence staining of in vitro cultured canine M0-, M1-, and M2-macrophages labeled with prototypic literature-based antibodies for the M1- (CD16, CD32, MHC class II, and iNOS) and M2-phenotype (CD163, CD206, and arginase 1), respectively.
A-C) Low to moderate membranous staining of M0-, M1-, and M2-macrophages for CD16. D-F) Likewise, CD32 shows a low to moderate staining in all three treatment conditions. G-I) M0-, M1-, and M2-macrophages demonstrate a moderate to high membranous staining with CD163. J-L) Intense membranous staining of M0-, M1-, and M2-macrophages with an anti-MHC class II antibody. M-O) Strong intracytoplasmic labeling of macrophages in all treatments (polarity 0, 1, 2) for inducible nitric oxide synthase (iNOS). P-R) High intracytoplasmic expression of arginase 1 in small/roundish, amoeboid, and spindeloid macrophages as well as in multinucleated giant cells (MNGs). a-f) Statistical evaluation of the mean expression percentages of prototypic M1-/M2-markers evaluated in 5 dogs and related to the polarization state of the macrophages (polarity 0, 1, 2). Note that, except for MHC class II, none of the remaining tested antigens (CD16, CD32, iNOS, CD163, and arginase-1) were differently expressed between canine M0-, M1-, and M2-macrophages (* = p≤0.05; Kruskal-Wallis-Test with pairwise Mann-Whitney-U-Tests). Scale bars = 100 μm. Nuclear counterstaining with bisbenzimide.
Fig 3Phenotypical characterization of canine M0-, M1-, and M2-macrophages.
A) Low membranous expression of CD206 antigen by small/roundish M0-macrophages. B) Moderate membranous staining of amoeboid M1-macrophages for CD206. C) Intense membranous expression of CD206 antigen by M2-macrophages. Scale bars = 100 μm. Nuclear counterstaining with bisbenzimide. D) The mean percentage of CD206-immunopositive cells is significantly higher in M2-macrophages as compared to both M1- and M0-macrophages (* = p≤0.05; Kruskal-Wallis-Test with pair-wise Mann-Whitney-U-Tests). E) The log2-transformed expression values of the probe set encoding for the gene CD206 is similarly significantly higher in M2-macrophages compared to both M1- and M0-macrophages (* = p≤0.05; Kruskal-Wallis-Test with pair-wise Mann-Whitney-U-Tests), thus confirming the results of the immunofluorescence investigation.
Summarized results of the functional annotation of the pairwise comparisons of differentially expressed probe sets (DEPs) in canine M0-, M1-, and M2-macrophages.
| Pairwise comparison | Differentially expressed probe sets | Up-/down-regulated probe sets | Enriched biological process categories | Enriched KEGG pathways |
|---|---|---|---|---|
| M1 | 3555 | Up: 1699 | • Organonitrogen compound metabolic process | • Metabolic pathways |
| Down: 1856 | • Positive regulation of immune response | • Hematopoietic cell lineage | ||
| M2 | 4831 | Up: 2467 | • Oxidation-reduction process | • Metabolic pathways |
| Down: 2364 | • Immune response-activating signal transduction | • T cell receptor signaling pathway | ||
| M2 | 3141 | Up: 1572 | • Mitotic spindle organization | • Cell cycle |
| Down: 1569 | • Response to other organism | • NOD-like receptor signaling pathway |
* employing Web-based Gene Set Analysis Toolkit (WebGestalt; http://bioinfo.vanderbilt.edu/webgestalt/) with default settings
adjusted p-value ≤0.05
List and subgrouping of the top hits of highly differentially expressed genes (fold change ≥ 50 or ≤ -50) in canine M1- vs. M0-macrophages.
| Gene name | Gene symbol | Fold change |
|---|---|---|
| Succinate receptor 1 | SUCNR1 | 212.94 |
| Syndecan 4 | SDC4 | 58.61 |
| Cholinergic receptor, nicotinic, alpha 9 (neuronal) | CHRNA9 | 53.74 |
| ADP-ribosylhydrolase like 2 | ADPRHL2 | 535.59 |
| Ceruloplasmin (ferroxidase) | CP | 161.88 |
| Epoxide hydrolase 2, cytoplasmic | EPHX2 | 119.72 |
| Ectonucleotide pyrophosphatase/phosphodiesterase 2 | ENPP2 | 117.43 |
| Interstitial collagenase-like | LOC489428 | 87.83 |
| E3 ubiquitin-protein ligase NEURL3-like | LOC102152163 | 86.20 |
| NOP2/Sun domain family, member 7 | NSUN7 | 66.00 |
| Nucleoredoxin | NXN | 64.78 |
| WNK lysine deficient protein kinase 2 | WNK2 | 52.35 |
| Interleukin 6 (interferon, beta 2) | IL6 | 252.32 |
| Chemokine (C-C motif) ligand 22 | CCL22 | 187.96 |
| Chemokine (C-X-C motif) receptor 7 | ACKR3 | 178.18 |
| Interleukin 22 receptor, alpha 2 | IL22RA2 | 116.00 |
| Chemokine (C-X-C motif) ligand 14 | CXCL14 | 108.55 |
| Chemokine (C-C motif) ligand 17 | CCL17 | 95.26 |
| Chemokine (C-C motif) ligand 20 | CCL20 | 67.90 |
| Chitinase 3-like 1 (cartilage glycoprotein-39) | CHI3L1 | 83.25 |
| Clusterin | CLU | 66.23 |
| Ras homolog family member U | RHOU | 446.23 |
| Interferon, alpha-inducible protein 6 | IFI6 | 269.13 |
| CXADR-like membrane protein | CLMP | 213.81 |
| Retinoic acid induced 14 | RAI14 | 118.86 |
| CD209 molecule | CD209 | -345.12 |
| CD180 molecule | CD180 | -75.00 |
| Killer cell lectin-like receptor subfamily G, member 1 | KLRG1 | -66.25 |
| Collectin sub-family member 12 | COLEC12 | -61.81 |
| Complement component 3a receptor 1 | C3AR1 | -55.16 |
| Carboxypeptidase M | CPM | -134.50 |
| N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase) | NPL | -78.98 |
| Cathepsin E | CTSE | -76.30 |
| Chemokine (C-X-C motif) ligand 12 | CXCL12 | -401.92 |
| Pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) | PPBP | -100.42 |
| Interleukin 2 | IL2 | -95.84 |
| Interleukin 1 receptor, type II | IL1R2 | -79.71 |
| Chemokine (C-C motif) receptor 3 | CCR3 | -51.05 |
| Lipocalin 2 | LCN2 | -180.73 |
| CD5 molecule-like | CD5L | -153.48 |
| Secreted phosphoprotein 2, 24kDa | SPP2 | -51.92 |
| Coagulation factor XIII, A1 polypeptide | F13A1 | -3305.03 |
| Fatty acid binding protein 4, adipocyte | FABP4 | -370.34 |
| G protein-coupled receptor 116 | GPR116 | -130.89 |
| Interferon-induced transmembrane protein 3-like | LOC606890 | -114.16 |
| Plexin domain containing 2 | PLXDC2 | -67.07 |
| ADP-ribosylation factor-like 4C | ARL4C | -56.52 |
| Cyclin J-like | CCNJL | -54.76 |
| Thrombospondin 1 | THBS1 | -53.38 |
List and subgrouping of the top hits of highly differentially expressed genes (fold change ≥ 50 or ≤ -50) in canine M2- vs. M0-macrophages.
| Gene name | Gene symbol | Fold change |
|---|---|---|
| Lymphatic vessel endothelial hyaluronan receptor 1 | LYVE1 | 322.32 |
| Succinate receptor 1 | SUCNR1 | 151.91 |
| CD1e molecule | CD1E | 147.40 |
| Mannose receptor, C type 1 | MRC1 | 104.41 |
| Tetraspanin 7 | TSPAN7 | 83.25 |
| Junctional adhesion molecule 3 | JAM3 | 78.46 |
| Anthrax toxin receptor 1 | ANTXR1 | 72.95 |
| Membrane-spanning 4-domains, subfamily A, member 2 | MS4A2 | 54.98 |
| C-type lectin domain family 4, member G | CLEC4G | 54.14 |
| ADP-ribosylhydrolase like 2 | ADPRHL2 | 614.52 |
| Guanine deaminase | GDA | 174.44 |
| Ubiquitin-conjugating enzyme E2 C-like | LOC481325 | 151.23 |
| Ribonucleotide reductase M2 | RRM2 | 131.03 |
| Fructose-1,6-bisphosphatase 1 | FBP1 | 57.95 |
| Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | MMP9 | 56.03 |
| Lipoprotein lipase | LPL | 52.03 |
| Trimethyllysine hydroxylase, epsilon | TMLHE | 51.05 |
| 3-hydroxybutyrate dehydrogenase, type 2 | BDH2 | 50.68 |
| Chemokine (C-C motif) ligand 24 | CCL24 | 1060.82 |
| Chemokine (C-X-C motif) receptor 7 | ACKR3 | 390.67 |
| Chemokine (C-C motif) ligand 17 | CCL17 | 209.36 |
| Chemokine (C-C motif) ligand 13 | CCL13 | 172.58 |
| Interleukin 13 receptor, alpha 2 | IL13RA2 | 170.59 |
| Transforming growth factor, beta 2 | TGFB2 | 61.84 |
| Nephronectin | NPNT | 444.07 |
| Norrie disease (pseudoglioma) | NDP | 213.72 |
| Endothelin 1 | EDN1 | 115.81 |
| Cystatin 9 (testatin) | CST9 | 58.21 |
| Sodium channel, voltage-gated, type II, beta subunit | SCN2B | 1061.28 |
| Caldesmon 1 | CALD1 | 224.66 |
| CXADR-like membrane protein | CLMP | 169.27 |
| SHC SH2-domain binding protein 1 | SHCBP1 | 117.77 |
| Dynamin 1 | DNM1 | 112.78 |
| NACC family member 2, BEN and BTB (POZ) domain containing | NACC2 | 110.49 |
| Retinoic acid induced 14 | RAI14 | 84.35 |
| Scinderin | SCIN | 71.66 |
| Kinesin family member 23 | KIF23 | 66.78 |
| Kinesin family member 11 | KIF11 | 64.20 |
| Cfa-mir-125b-2 | cfa-mir-125b-2 | 58.78 |
| AHNAK nucleoprotein | AHNAK | 57.19 |
| NUF2, NDC80 kinetochore complex component | NUF2 | 54.62 |
| Integrin, beta 8 | ITGB8 | -199.37 |
| Lymphocyte antigen 6 complex, locus E | LY6E | -116.70 |
| T cell receptor delta constant | TRDC | -112.73 |
| Natural cytotoxicity triggering receptor 3 | NCR3 | -105.99 |
| Selectin L | SELL | -95.45 |
| Sialic acid binding Ig-like lectin 1, sialoadhesin | SIGLEC1 | -91.39 |
| Killer cell lectin-like receptor subfamily D, member 1 | KLRD1 | -87.12 |
| Killer cell lectin-like receptor subfamily B, member 1 | KLRB1 | -74.56 |
| Membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6) | MPP6 | -72.60 |
| Purinergic receptor P2Y, G-protein coupled, 14 | P2RY14 | -71.69 |
| T cell receptor beta constant 2 | TRBC2 | -64.26 |
| TCR gamma alternate reading frame protein | TARP | -62.39 |
| Fc receptor-like A | FCRLA | -60.06 |
| Potassium channel, subfamily K, member 5 | KCNK5 | -58.16 |
| Purinergic receptor P2X, ligand-gated ion channel, 5 | P2RX5 | -58.16 |
| Natural killer cell group 7 sequence | NKG7 | -57.26 |
| CD69 molecule | CD69 | -54.53 |
| CD7 molecule | CD7 | -52.57 |
| Interferon stimulated exonuclease gene 20kDa | ISG20 | -514.04 |
| Prostaglandin E synthase | PTGES | -382.20 |
| Cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial | CMPK2 | -266.50 |
| Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) | GZMA | -131.27 |
| Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) | GZMB | -130.63 |
| Hexokinase 3 (white cell) | HK3 | -127.10 |
| Ubiquitin specific peptidase 18 | USP18 | -81.72 |
| Phospholipase A1 member A | PLA1A | -72.65 |
| Cathepsin E | CTSE | -72.13 |
| GTP cyclohydrolase 1 | GCH1 | -66.29 |
| Chymase 1, mast cell | CMA1 | -61.45 |
| Phospholipid scramblase 1-like | LOC611500 | -61.09 |
| Chemokine (C-X-C motif) ligand 12 | CXCL12 | -417.05 |
| Interleukin 2 | IL2 | -195.40 |
| Interleukin 7 receptor | IL7R | -66.71 |
| Transforming growth factor, beta receptor III | TGFBR3 | -50.94 |
| Lipocalin 2 | LCN2 | -217.74 |
| Adrenomedullin | ADM | -100.37 |
| Radical S-adenosyl methionine domain containing 2 | RSAD2 | -559.34 |
| Interferon-induced transmembrane protein 3-like | LOC606890 | -435.57 |
| ISG15 ubiquitin-like modifier | ISG15 | -254.32 |
| Apolipoprotein L, 5 | APOL5 | -200.23 |
| Fatty acid binding protein 4, adipocyte | FABP4 | -182.17 |
| Interferon-induced protein with tetratricopeptide repeats 1 | IFIT1 | -142.72 |
| Interferon regulatory factor 4-like | LOC609817 | -118.68 |
| Carcinoembryonic antigen-related cell adhesion molecule 25 | CAECAM1 | -113.27 |
| Interferon regulatory factor 7 | IRF7 | -102.93 |
| OCIA domain containing 2 | OCIAD2 | -100.84 |
| Piwi-like RNA-mediated gene silencing 4 | PIWIL4 | -97.75 |
| Synaptotagmin-like 3 | SYTL3 | -94.94 |
| Testis expressed 14 | TEX14 | -92.58 |
| Myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) | MX1 | -91.32 |
| Structural maintenance of chromosomes flexible hinge domain containing 1 | SMCHD1 | -84.97 |
| Interferon-induced transmembrane protein 1-like | LOC475935 | -83.91 |
| eukaryotic peptide chain release factor GTP-binding subunit ERF3B-like | LOC480921 | -74.06 |
| Lactotransferrin | LTF | -72.08 |
| DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 | DDX58 | -69.54 |
| TNFAIP3 interacting protein 3 | TNIP3 | -58.03 |
| Syntrophin, beta 1 (dystrophin-associated protein A1, 59kDa, basic component 1) | SNTB1 | -55.46 |
| Src kinase associated phosphoprotein 1 | SKAP1 | -50.58 |
List and subgrouping of the top hits of highly differentially expressed genes (fold change ≥ 50 or ≤ -50) in M2- vs. M1-macrophages.
| Gene name | Gene symbol | Fold change |
|---|---|---|
| Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide | FCER1A | 376.89 |
| CD209 molecule | CD209 | 335.12 |
| Lymphatic vessel endothelial hyaluronan receptor 1 | LYVE1 | 321.11 |
| C-type lectin domain family 4, member G | CLEC4G | 183.13 |
| Collectin sub-family member 12 | COLEC12 | 181.04 |
| Junctional adhesion molecule 3 | JAM3 | 145.24 |
| Membrane-spanning 4-domains, subfamily A, member 2 | MS4A2 | 137.95 |
| Stabilin 1 | STAB1 | 127.60 |
| Mannose receptor, C type 1 | MRC1 | 52.68 |
| Solute carrier family 15 (oligopeptide transporter), member 1 | SLC15A1 | 52.03 |
| Fructose-1,6-bisphosphatase 1 | FBP1 | 149.73 |
| Uronyl-2-sulfotransferase | UST | 85.20 |
| Alanyl (membrane) aminopeptidase | ANPEP | 82.13 |
| Lipoprotein lipase | LPL | 57.39 |
| Chemokine (C-C motif) ligand 24 | CCL24 | 1050.11 |
| Transforming growth factor, beta 2 | TGFB2 | 66.97 |
| CD5 molecule-like | CD5L | 209.01 |
| Secreted phosphoprotein 2, 24kDa | SPP2 | 121.14 |
| Nephronectin | NPNT | 105.07 |
| Secretogranin V (7B2 protein) | SCG5 | 82.69 |
| Complement component 3 | C3 | 67.78 |
| Cystatin 9 (testatin) | CST9 | 58.53 |
| Coagulation factor XIII, A1 polypeptide | F13A1 | 1309.86 |
| Sodium channel, voltage-gated, type II, beta subunit | SCN2B | 1120.45 |
| Dynamin 1 | DNM1 | 247.10 |
| Caldesmon 1 | CALD1 | 239.74 |
| Rho GTPase activating protein 6 | ARHGAP6 | 147.58 |
| Fibronectin 1 | FN1 | 141.81 |
| Cfa-mir-125b-2 | cfa-mir-125b-2 | 103.61 |
| Plexin domain containing 2 | PLXDC2 | 71.70 |
| Transforming growth factor, beta-induced, 68kDa | TGFBI | 59.20 |
| G protein-coupled receptor 116 | GPR116 | 51.83 |
| Purinergic receptor P2Y, G-protein coupled, 14 | P2RY14 | -344.22 |
| Solute carrier family 39 (zinc transporter), member 14 | SLC39A14 | -200.01 |
| Integrin, beta 8 | ITGB8 | -134.58 |
| Transmembrane protein 150C | TMEM150C | -103.02 |
| Transmembrane protein 176A | TMEM176A | -78.17 |
| Solute carrier family 22, member 15 | SLC22A15 | -58.69 |
| Prostaglandin E synthase | PTGES | -1274.66 |
| Epoxide hydrolase 2, cytoplasmic | EPHX2 | -222.01 |
| Interferon stimulated exonuclease gene 20kDa | ISG20 | -187.95 |
| Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | PTGS2 | -183.48 |
| E3 ubiquitin-protein ligase NEURL3-like | LOC102152163 | -156.11 |
| Indoleamine 2,3-dioxygenase 2 | IDO2 | -127.88 |
| STEAP family member 4 | STEAP4 | -92.42 |
| Ceruloplasmin (ferroxidase) | CP | -90.30 |
| Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) | GZMB | -69.42 |
| Phospholipase A2, group XVI-like | LOC476045 | -57.39 |
| cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial | CMPK2 | -57.00 |
| WNK lysine deficient protein kinase 2 | WNK2 | -52.30 |
| Interleukin-1 receptor-associated kinase 3 | IRAK3 | -50.40 |
| Chemokine (C-X-C motif) receptor 3 | CXCR3 | -140.97 |
| Chemokine (C-C motif) ligand 20 | CCL20 | -119.64 |
| Interleukin 6 (interferon, beta 2) | IL6 | -69.50 |
| Tumor necrosis factor | TNF | -55.63 |
| Complement component 2 | C2 | -78.67 |
| Peptidase inhibitor 3, skin-derived | PI3 | -235.52 |
| TNFAIP3 interacting protein 3 | TNIP3 | -178.37 |
| Ras homolog family member U | RHOU | -168.17 |
| Radical S-adenosyl methionine domain containing 2 | RSAD2 | -82.43 |
| Cochlin | COCH | -70.23 |
| Interferon, alpha-inducible protein 6 | IFI6 | -68.46 |
| multiple C2 domains, transmembrane 2 | MCTP2 | -66.09 |
| Fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) | FSCN1 | -58.64 |
| Interferon regulatory factor 4-like | LOC609817 | -50.92 |
| ISG15 ubiquitin-like modifier | ISG15 | -50.28 |
Fig 4Hierarchical clustering analysis.
Unsupervised hierarchical clustering analysis of the median centered, log2-transformed expression values of 6358 differentially expressed probe sets in canine polarized macrophages as obtained by TM4 MultiExperimentViewer with default settings (Euclidean distance; complete linkage), depicted on a color scale from red (relatively high expression) to green (relatively low expression). A) The analysis identified 9 distinct clusters (I-IX) based on similarities as well as differences in the expression intensity of canine polarized macrophages. Two out of these 9 clusters (VIII and VI) visually displayed an expression profile that was clearly associated with either the M1- or M2-phenotype. B) Functional annotation of the M1-cluster (magnified from A) using Web-based Gene Set Analysis Toolkit (WebGestalt) identified the enriched biological process category “respiratory burst” (adjusted p-value≤0.05). C) The M2-cluster (magnified from A) is associated with enriched biological GO terms such as “M phase of mitotic cell cycle” and “mitotic spindle organization” (adjusted p-value≤0.05).
Fig 5Comparative evaluation of canine M1- and M2-associated differentially expressed genes (M1 = 404; M2 = 700) with established literature-based human and murine orthologous genes (A) and detection of polarization-specific biomarkers employing supervised clustering with a K-nearest-neighbors algorithm and correlation-based feature selection using Prophet (B, C). A) The Venn diagram depicts the numbers and intersections of differential and common canine M1- and M2-genes with literature-based human and murine genes. The majority of literature-based M1- (65 genes = 57+8) and M2-markers (58 genes = 44+11+3) did not comply with the present microarray data upon canine macrophages. However, overlapping expression of 8 genes for the M1-phenotype and 11 genes for the M2-phenotype was identified. The genes of the intersections, not specifically mentioned in the figure, are listed in S4 Table B) Biomarker selection detected 4 highly specific probe sets for annotated by the mammalian carboxypeptidase inhibitor latexin (LXN) to be highly correlated to the M1-phenotype. The boxplots depict the significantly enhanced log2-transformed expression values for LXN in M1-macrophages as compared to both M0- and M2-macrophages (p = 0.002), as well as between M0- and M2-macrophages (p = 0.002). C) For the M2-phenotype, the most significant predicted biomarker was high affinity receptor for IgE, i.e. membrane-spanning 4-domains, subfamily A, member 2 (MS4A2). The expression data of M2-macrophages show significantly higher log2-transformed expression values as compared to both M0- and M1-macrophages (p = 0.002) as well as between M0- and M1-macrophages (p = 0.002). Asterisks indicate significance (Kruskal-Wallis-Test with subsequent pairwise Mann-Whitney-U-Tests).
Top 50 candidate M1-macrophage associated probesets, which were upregulated in M1- vs. M0-macrophages and simultaneously downregulated in M2- vs. M1-macrophages.
| Probe Set ID | Gene Symbol | Fold change M1 vs. M0 | Fold change M2 vs. M1 |
|---|---|---|---|
| Cfa.12190.1.A1_at | PTGES | 3.34 | -1274.66 |
| CfaAffx.30585.1.S1_s_at | PTGES | 4.99 | -1136.51 |
| CfaAffx.30585.1.S1_at | PTGES | 4.94 | -517.22 |
| CfaAffx.927.1.S1_at | P2RY14 | 4.80 | -344.22 |
| Cfa.20456.1.S1_at | IFI6 | 269.13 | -284.48 |
| CfaAffx.15155.1.S1_s_at | PI3 | 27.22 | -235.52 |
| Cfa.574.1.A1_at | EPHX2 | 119.72 | -222.01 |
| Cfa.18083.1.S1_s_at | SLC39A14 | 15.89 | -212.19 |
| CfaAffx.14855.1.S1_s_at | SLC39A14 | 13.48 | -200.01 |
| Cfa.3449.1.S1_s_at | PTGS2 | 27.78 | -183.48 |
| Cfa.15554.1.A1_at | TNIP3 | 3.07 | -178.37 |
| Cfa.9253.1.A1_at | RHOU | 446.23 | -168.17 |
| Cfa.12477.1.A1_at | LOC102152163 | 86.20 | -156.11 |
| Cfa.16339.1.S1_at | CXCR3 | 5.70 | -140.97 |
| Cfa.10779.1.A1_at | IDO2 | 28.65 | -127.88 |
| CfaAffx.13394.1.S1_s_at | EPHX2 | 110.24 | -122.12 |
| Cfa.15812.1.S1_at | CCL20 | 67.90 | -119.64 |
| Cfa.1856.1.S1_at | TMEM150C | 40.36 | -103.02 |
| Cfa.2878.1.A1_s_at | CP | 425.52 | -96.02 |
| CfaAffx.3697.1.S1_at | STEAP4 | 11.45 | -92.42 |
| CfaAffx.13209.1.S1_s_at | CP | 161.88 | -90.30 |
| Cfa.8846.1.A1_s_at | C2 /// CFB | 4.39 | -78.67 |
| CfaAffx.7919.1.S1_at | TMEM176A | 19.58 | -78.17 |
| CfaAffx.1718.1.S1_at | TNF | 47.17 | -71.34 |
| Cfa.3528.1.S1_s_at | IL6 | 252.32 | -69.50 |
| Cfa.20456.1.S1_s_at | IFI6 | 68.64 | -68.46 |
| CfaAffx.17110.1.S1_s_at | MCTP2 | 2.69 | -66.09 |
| CfaAffx.15348.1.S1_at | SLC22A15 | 15.67 | -58.69 |
| CfaAffx.24565.1.S1_at | FSCN1 | 35.83 | -58.64 |
| Cfa.12164.1.A1_at | LOC476045 | 5.65 | -57.39 |
| Cfa.54.1.S1_s_at | TNF | 47.20 | -55.63 |
| Cfa.11870.1.A1_at | PI3 | 17.25 | -52.33 |
| Cfa.4359.1.S1_at | WNK2 | 52.35 | -52.30 |
| CfaAffx.1510.1.S1_s_at | IRAK3 | 10.70 | -50.40 |
| CfaAffx.15202.1.S1_s_at | SDC4 | 58.61 | -49.56 |
| CfaAffx.1352.1.S1_s_at | IL22RA2 | 116.00 | -48.48 |
| CfaAffx.26233.1.S1_s_at | CXCR3 | 32.55 | -47.23 |
| CfaAffx.17136.1.S1_s_at | MCTP2 | 6.25 | -46.94 |
| CfaAffx.24086.1.S1_at | KMO | 23.66 | -46.48 |
| CfaAffx.15086.1.S1_s_at | BMP1 | 43.14 | -43.31 |
| CfaAffx.261.1.S1_at | HCAR3 | 13.88 | -42.20 |
| Cfa.18962.1.S1_s_at | SGK1 | 20.11 | -39.12 |
| Cfa.3719.1.S1_s_at | QPCT | 22.78 | -38.99 |
| Cfa.4926.1.A1_s_at | LOC476045 | 5.41 | -37.14 |
| CfaAffx.6260.1.S1_at | C18H7orf10 | 43.19 | -36.13 |
| Cfa.6458.1.A1_s_at | C2 /// CFB | 5.05 | -36.01 |
| Cfa.8282.1.A1_s_at | KBTBD7 | 3.64 | -35.38 |
| CfaAffx.8143.1.S1_at | KBTBD7 | 2.59 | -35.14 |
| Cfa.21252.1.S1_s_at | ENPP2 | 188.74 | -34.85 |
| CfaAffx.16422.1.S1_s_at | CCL20 | 33.43 | -34.83 |
Top 50 candidate M2-macrophage associated probesets, which were upregulated in M2- vs. M0-macrophages and simultaneously upregulated in M2- vs. M1-macrophages.
| Probe Set ID | Gene Symbol | Fold change M2 vs. M0 | Fold change M2 vs. M1 |
|---|---|---|---|
| Cfa.11125.1.A1_at | SCN2B | 1061.28 | 1120.45 |
| Cfa.15823.1.S1_at | CCL24 | 1060.82 | 1050.11 |
| CfaAffx.18273.1.S1_at | FCER1A | 35.63 | 922.72 |
| CfaAffx.20721.1.S1_s_at | CCL24 | 819.06 | 819.06 |
| Cfa.17541.1.S1_s_at | FBP1 | 160.02 | 748.69 |
| CfaAffx.2850.1.S1_s_at | FBP1 | 57.95 | 422.21 |
| Cfa.3663.1.A1_s_at | FCER1A | 21.07 | 376.89 |
| Cfa.3707.1.A1_at | FN1 | 12.68 | 360.42 |
| CfaAffx.12229.1.S1_at | LYVE1 | 322.32 | 321.11 |
| Cfa.10966.1.A1_at | DNM1 | 112.78 | 247.10 |
| Cfa.6272.1.S1_at | CALD1 | 224.66 | 239.74 |
| CfaAffx.1504.1.S1_s_at | UST | 7.71 | 226.47 |
| Cfa.2693.1.A1_at | LOC102152647 | 194.28 | 194.28 |
| Cfa.3707.1.A1_s_at | FN1 | 7.26 | 188.32 |
| CfaAffx.28024.1.S1_at | CLEC4G | 54.14 | 183.13 |
| CfaAffx.16206.1.S1_at | MS4A2 | 110.05 | 167.77 |
| Cfa.6369.1.A1_at | FBP1 | 26.98 | 149.73 |
| Cfa.20346.1.S1_at | ARHGAP6 | 37.99 | 147.58 |
| Cfa.1705.1.A1_at | JAM3 | 78.46 | 145.24 |
| Cfa.3662.1.S1_at | MS4A2 | 54.98 | 137.95 |
| Cfa.19567.1.S1_at | UST | 8.05 | 120.81 |
| CfaAffx.16206.1.S1_s_at | MS4A2 | 76.56 | 108.61 |
| Cfa.3774.1.A1_s_at | ANPEP | 25.55 | 105.73 |
| Cfa.14465.1.S1_at | NPNT | 444.07 | 105.07 |
| Cfa.688.1.S1_at | cfa-mir-125b-2 | 58.78 | 103.61 |
| CfaAffx.7700.1.S1_s_at | MRC1 | 136.99 | 89.14 |
| Cfa.2468.1.A1_at | UST | 6.54 | 85.20 |
| Cfa.10794.1.A1_at | SCG5 | 6.75 | 82.69 |
| Cfa.20798.1.S1_at | ANPEP | 14.09 | 82.13 |
| CfaAffx.14701.1.S1_s_at | STAB1 | 4.00 | 81.41 |
| CfaAffx.28463.1.S1_at | C3 | 36.53 | 76.45 |
| Cfa.12240.1.A1_at | C3 | 44.14 | 67.78 |
| CfaAffx.16904.1.S1_s_at | TGFB2 | 61.84 | 66.97 |
| CfaAffx.7365.1.S1_at | CST9 | 58.21 | 58.53 |
| CfaAffx.15901.1.S1_s_at | LPL | 52.03 | 57.39 |
| CfaAffx.7698.1.S1_at | MRC1 | 104.41 | 52.68 |
| Cfa.78.1.S1_s_at | SLC15A1 | 14.65 | 52.03 |
| CfaAffx.27914.1.S1_s_at | IL13RA2 | 170.59 | 46.70 |
| Cfa.19638.1.S1_s_at | TMLHE | 51.05 | 45.55 |
| CfaAffx.22229.1.S1_at | GPR34 | 6.30 | 42.39 |
| CfaAffx.21392.1.S1_s_at | FKBP7 | 25.81 | 40.60 |
| CfaAffx.19151.1.S1_s_at | ADCY4 | 14.07 | 39.02 |
| Cfa.11222.1.A1_s_at | FAM185A | 23.07 | 38.03 |
| Cfa.10053.1.A1_at | RAB40B | 48.86 | 37.88 |
| CfaAffx.24797.1.S1_at | EPHX1 | 3.75 | 36.82 |
| Cfa.1930.1.S1_at | MRC1 | 25.70 | 36.76 |
| Cfa.3367.1.A1_at | TGFB2 | 36.49 | 36.58 |
| Cfa.15824.1.S1_at | CCL13 | 172.58 | 34.71 |
| Cfa.14297.1.A1_s_at | MAOB | 33.75 | 33.75 |
| Cfa.12621.1.A1_at | LRP4 | 7.01 | 33.01 |
Fig 6Protein expression of the predicted biomarkers latexin and MS4A2 in canine M0-, M1-, and M2-macrophages.
A) Expression of latexin in non-stimulated canine M0-macrophages. B) Expression of latexin in canine M1-macrophages. C) Expression of latexin in canine M2-macrophages. D) Expression of MS4A2 in canine M0-macrophages. E) Expression of MS4A2 in canine M1-macrophages. F) Expression of MS4A2 in canine M2-macrophages. A-F) Scale bars = 100 μm. Nuclear counterstaining with bisbenzimide. G) Dot plots illustrating a significantly higher percentage of immunopositive cells in canine M1- and M2-macrophages as compared to M0-macrophages (One-factorial ANOVA with group-wise t-tests, astrerisk = p<0.05). H) Dot plot showing lack of statistical differences in the percentage of immunopositive cells for MS4A2 in canine M0-, M1-, and M2-macrophages.